<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01092559</url>
  </required_header>
  <id_info>
    <org_study_id>P2010-001</org_study_id>
    <nct_id>NCT01092559</nct_id>
  </id_info>
  <brief_title>Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide</brief_title>
  <acronym>PILOT</acronym>
  <official_title>An Open Label Pilot Study Evaluating Preliminary Safety and Performance of the GeNO Nitrosyl Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geno LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geno LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label phase 2 pilot study designed to evaluate the safety, tolerability and
      device performance of the GeNO nitrosyl delivery system during right heart catheterization
      (RHC) in participants with pulmonary arterial hypertension (PAH). All participants will
      receive inhaled nitric oxide in oxygen or nitric oxide in air delivered by nasal cannula.
      Hemodynamics, clinical laboratory and clinical assessment data will be collected on all
      participants to evaluate safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TREATMENT/FOLLOW-UP:

      Participants meeting eligibility criteria will receive open label nitric oxide at 80 ppm via
      a nasal cannula. Hemodynamic clinical laboratory and clinical assessment data will be
      collected at baseline, after 15 minutes of inhaled nitric oxide administration, post RHC
      procedure and at hospital discharge. Day 5 +/- 3 post RHC, telephone contact to assess
      general health status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and Severity of Treatment Emergent Adverse Events; Unanticipated Adverse Device Effects and Changes From Baseline to End-of-study in Clinical Lab Parameters and Vital Signs.</measure>
    <time_frame>through Day 30 Follow-up Period</time_frame>
    <description>Adverse Event Severity [through Day 30 Follow-Up Period]
Unanticipated Device Effects: any system malfunction, damage or NO2 threshold monitor alarms [through discharge from Treatment Period]
Laboratory Tests: Hematology (CBC with differential), Chemistry (glucose, BUN, creatinine, sodium, potassium, carbon dioxide, creatinine kinase), Activated Clotting Test or Prothrombin Time, arterial blood gas, and methemoglobin.
[through discharge from Treatment Period]
Vital Signs: pulse, blood pressure, respiratory rate [through discharge from Treatment Period]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adequacy of Device Design and Suitability of the Instructions for Use by the Clinician Using a Device Performance Evaluation</measure>
    <time_frame>through Treatment Period</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>nitric oxide via GeNO Nitrosyl system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitric Oxide via GeNO Nitrosyl system</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitric Oxide generated by the GeNO nitrosyl delivery system</intervention_name>
    <description>single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.</description>
    <arm_group_label>nitric oxide via GeNO Nitrosyl system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a confirmed diagnosis of PAH, WHO Group 1.

          -  WHO Functional Class II or III equivalent, PAH.

          -  Have been clinically stable with regard to signs and symptoms of PAH for at least 30
             days prior to RHC.

          -  May be receiving approved mono therapies or combination PAH therapies.

          -  Females that are surgically sterile or post-menopausal. Females of chil-bearing
             potential must have negative pregnancy test and must be practicing adequate birth
             control.

        Exclusion Criteria:

          -  Have had a new type of chronic therapy (including but not limited to oxygen, a
             different category of vasodilator, a diuretic, digoxin) for PAH added within (1) month
             of RHC.

          -  Have any PAH medication except for anticoagulants discontinued within the week prior
             to RHC.

          -  Have evidence of significant parenchymal lung disease as evidenced by pulmonary
             function tests within the last six months

          -  CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly,
             telangiectasia) syndrome

          -  Have a history of uncontrolled sleep apnea within three months of RHC.

          -  Have a history of hemodynamically significant left-sided heart disease

          -  Have evidence of left-sided heart disease

          -  Have any other disease that is associated with pulmonary hypertension (e.g. congenital
             systemic-to-pulmonary shunt, sickle cell anemia, schistosomiasis).

          -  Documented uncontrolled systemic hypertension as evidenced by systolic blood pressure
             greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg.

          -  Have used prescription appetite suppressants within 3 months prior to wean/transition.

          -  Have chronic kidney disease stage IV or worse or the requirement for dialysis.

          -  Be receiving an investigational drug, have in place an investigational device, or have
             participated in an investigational drug study within the past 30 days.

          -  Have had an atrial septostomy.

          -  Have anemia (hemoglobin &lt;10 g/dL), active infection or any other ongoing condition
             that would interfere with the interpretation of study assessments.

          -  Have any serious or life-threatening disease other than conditions associated with PAH
             (e.g. malignancy requiring aggressive chemotherapy, renal dialysis, etc.).

          -  Have unstable psychiatric status or be mentally incapable of understanding the
             objectives, nature or consequences of the trial

          -  Participant is pregnant or lactating

          -  Significant, ongoing alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tufts</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2010</study_first_posted>
  <results_first_submitted>April 18, 2013</results_first_submitted>
  <results_first_submitted_qc>April 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2013</results_first_posted>
  <last_update_submitted>April 18, 2013</last_update_submitted>
  <last_update_submitted_qc>April 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnostic Techniques and Procedures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nitric Oxide Via GeNO Nitrosyl System</title>
          <description>Nitric Oxide generated by the GeNO nitrosyl delivery system : single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nitric Oxide Via GeNO Nitrosyl System</title>
          <description>Nitric Oxide via GeNO Nitrosyl System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="15.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Treatment Emergent Adverse Events; Unanticipated Adverse Device Effects and Changes From Baseline to End-of-study in Clinical Lab Parameters and Vital Signs.</title>
        <description>Adverse Event Severity [through Day 30 Follow-Up Period]
Unanticipated Device Effects: any system malfunction, damage or NO2 threshold monitor alarms [through discharge from Treatment Period]
Laboratory Tests: Hematology (CBC with differential), Chemistry (glucose, BUN, creatinine, sodium, potassium, carbon dioxide, creatinine kinase), Activated Clotting Test or Prothrombin Time, arterial blood gas, and methemoglobin.
[through discharge from Treatment Period]
Vital Signs: pulse, blood pressure, respiratory rate [through discharge from Treatment Period]</description>
        <time_frame>through Day 30 Follow-up Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide Via GeNO Nitrosyl System</title>
            <description>Nitric Oxide generated by the GeNO nitrosyl delivery system : single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence and Severity of Treatment Emergent Adverse Events; Unanticipated Adverse Device Effects and Changes From Baseline to End-of-study in Clinical Lab Parameters and Vital Signs.</title>
          <description>Adverse Event Severity [through Day 30 Follow-Up Period]
Unanticipated Device Effects: any system malfunction, damage or NO2 threshold monitor alarms [through discharge from Treatment Period]
Laboratory Tests: Hematology (CBC with differential), Chemistry (glucose, BUN, creatinine, sodium, potassium, carbon dioxide, creatinine kinase), Activated Clotting Test or Prothrombin Time, arterial blood gas, and methemoglobin.
[through discharge from Treatment Period]
Vital Signs: pulse, blood pressure, respiratory rate [through discharge from Treatment Period]</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adequacy of Device Design and Suitability of the Instructions for Use by the Clinician Using a Device Performance Evaluation</title>
        <time_frame>through Treatment Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nitric Oxide Via GeNO Nitrosyl System</title>
            <description>Nitric Oxide generated by the GeNO nitrosyl delivery system : single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Adequacy of Device Design and Suitability of the Instructions for Use by the Clinician Using a Device Performance Evaluation</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nitric Oxide Via GeNO Nitrosyl System</title>
          <description>Nitric Oxide generated by the GeNO nitrosyl delivery system : single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Development</name_or_title>
      <organization>GeNO, LLC</organization>
      <phone>321-785-2613</phone>
      <email>matthew.rush@genollc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

